UT San Antonio’s $38 Million Bet on Healthy Aging

The UT Health campus buildings are peacefully situated beneath a broad Texas sky on a beautiful afternoon in San Antonio. With coffee cups in hand, medical students meander between shaded pathways and glass research labs as the routine of an academic health center takes shape. However, a research that could subtly alter people’s perceptions of aging is developing behind one set of lab doors.

Through its UT Health academic medical center, the University of Texas at San Antonio has obtained up to $38 million in government funding to spearhead what might be the first statewide clinical trial with a specific focus on healthy lifespan. The funding is provided by the Advanced Research Projects Agency for Health, or ARPA-H, a relatively new division of the U.S. Department of Health and Human Services that aims to advance innovative medical concepts into practical trials.

Key Information Overview

The Validation and Intervention Testing for Aging, Longevity and Healthspan study, or VITAL-H, is the project’s almost ambitious name. The effort’s greater hope is implied even by the term. Living well is more important than just living longer. The next phase of medical study may be defined by this change from lifetime to healthspan.

The underlying processes that gradually reduce physical resilience as people age have been studied by scientists for decades. Muscles deteriorate. The metabolism changes. The immune system loses its predictability. The question of whether those processes can be halted in typical, generally healthy persons prior to the onset of serious illness remains unsolved. The San Antonio study aims to test precisely that.

Three drugs that are now available on pharmacy shelves—rapamycin, dapagliflozin, and semaglutide—will be investigated in the VITAL-H experiment. The U.S. Food and Drug Administration has approved each for various medical diseases, but preliminary research suggests they may affect biological pathways linked to aging.

Repurposing existing medications is an approach that has gained traction in research circles. It can take decades and billions of dollars to develop completely new drugs. In contrast, repurposing known chemicals proceeds much more quickly.

There is a sense of lengthy history behind the scene when one stands inside the Barshop Institute, where a large portion of this work will take place. The organization has spent decades researching the biology of aging and has published studies that shed light on how cells disintegrate over time. The science is now leaving the laboratory.

Adults between the ages of 60 and 65—a period of life that doctors frequently refer to as the “critical window” of aging—will be the focus of the clinical experiment. Many people stay healthy during this time, but they start to show signs of mild physical decline, such as altered metabolism, slower recovery from sickness, and decreased stamina. According to researchers, this window might present a chance.

The concept was explained in very straightforward words by Andrew Brack, an ARPA-H program manager and the creator of the project’s larger PROSPR mission. He proposed testing whether aging actually had to result in incapacity or whether medical interventions could maintain independence for a longer period of time than previously believed. It’s a big question. It might be uncomfortable.

Over the past century, medical advancements have significantly increased human longevity; nonetheless, many individuals spend their last years managing chronic illnesses. Frailty, diabetes, and cardiovascular disease are frequently addressed separately rather than as parts of a bigger biological puzzle. A distinct viewpoint is suggested by the San Antonio study project.

Scientists are investigating if aging itself may be tackled earlier, akin to preventative maintenance for the human body, rather than treating problems after they manifest. Twenty years ago, this idea could have seemed theoretical, but it now seems more firmly rooted in molecular biology.

Dr. Elena Volpi, director of the Barshop Institute and a well-known authority in longevity science, is spearheading the initiative. Researchers on her team have dedicated a significant portion of their careers to the study of the interplay between cellular aging, metabolism, and muscle performance.

There’s something subtly determined about the atmosphere when you watch the institute’s labs in action. Researchers examining data projections on big displays, scientists modifying equipment, and graduate students discussing findings in the hallway.

The population of America is aging quickly. Millions of people will reach retirement age by 2030, putting further strain on long-term care facilities and healthcare systems. Even a few extra years of healthy, independent living could have far-reaching social and economic effects. Policymakers and investors have started to take notice.

In an effort to turn lab findings into treatments, biotech corporations and venture capital firms have become more interested in longevity science. The field is no longer regarded as fringe research due to the federal government’s involvement through ARPA-H. Rather, it is evolving into something more akin to a national priority.

The financing, according to Jennifer Sharpe Potter, senior executive vice president for research and innovation at UT San Antonio, marks a turning point in the university’s overall scientific development. The Barshop Institute has been mapping the biology of aging for many years. It has now been invited to spearhead a national initiative to test such ideas on actual individuals.

It’s difficult to ignore the change. Suddenly, one of the nation’s most ambitious longevity projects is centered around a regional research center.

Naturally, it is yet unknown if the trial will be successful. Clinical research frequently yields unexpected, and perhaps disappointing, results. Drugs that appear promising in preliminary studies don’t necessarily function similarly in larger populations.

However, as the sun sets behind the buildings on the UT Health campus, there is a feeling that something significant is about to start.